Structure Based Drug Discovery Articles & Analysis: Older
10 news found
Proteros biostructures GmbH, a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding. ...
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (US FDA) clearance of the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine ...
Earlier in his career, Dr. Varney pioneered structure-based drug design as a founding employee at Agouron, which delivered Viracept®, Xalkori®, and Inlyta®. ...
Atomwise, a leader in using artificial intelligence (AI) for small -molecule drug discovery, today announced it has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2021. ...
Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. ...
The grant funding will be used to discover novel compounds that can advance the development of novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the Gates Foundation’s global network of partners and funded investigators. Atomwise will provide AI-based drug discovery support to leading researchers to ...
Under the agreement, GC Pharma and Atomwise will explore potential targets with the goal to develop a small molecule, and orally administrable drug option for patients. This first and other subsequent targets will be virtually screened for small molecules using AtomNet®, Atomwise’s AI platform for drug discovery. The AtomNet® ...
Atomwise created the first convolutional neural networks (CNN) for drug discovery. Since its founding in 2012 the company has continually developed and improved its AI-based drug discovery technology, called AtomNet®, which can screen over 16 billion synthesizable molecules against biological targets with ...
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today it has fifteen research collaborations underway with leading global universities to explore broad-spectrum therapies for COVID-19 and other coronaviruses. ...
Hansoh Pharma (3692:HK), a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the expansion of their strategic partnership for AI-accelerated drug discovery. ...